Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 181 to 195 of 292 results for breast cancer

  1. Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy [ID1347]

    Discontinued [GID-TA10264]

    Technology appraisal guidance
    Discontinued

  2. Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor [ID517]

    Discontinued [GID-TAG436]

    Technology appraisal guidance
    Discontinued

  3. Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)

    In development [GID-TA10261] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]

    Discontinued [GID-TAG411]

    Technology appraisal guidance
    Discontinued

  5. Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013 (PMG17)

    Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013

  6. Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)

    Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.

    Technology appraisal guidance
    Published
    27 May 2020
    View recommendations

    Sections for TA630

  7. Cough (acute): antimicrobial prescribing (NG120)

    This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.

    Antimicrobial prescribing guideline
    Published
    7 February 2019
    View recommendations

    Sections for NG120

  8. Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

    Discontinued [GID-TAG417]

    Technology appraisal guidance
    Discontinued

  9. NICE responds to failure of talks to reach price agreement on Enhertu

    Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged.

    News
    Last updated
    19 November 2024

  10. Breast reconstruction:- What are the long-term outcomes for breast reconstruction in women having radiotherapy to the chest wall?

    Recommendation ID NG101/3 Question Breast reconstruction:- What are the long-term outcomes for breast reconstruction in...

    Research recommendation
    Published
    11 December 2018

  11. Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)

    Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults.

    Technology appraisal guidance
    Last updated
    8 February 2021
    View recommendations

    Sections for TA185

  12. Caris Molecular Intelligence for guiding cancer treatment (MIB120)

    NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .

    Medtech innovation briefing
    Published
    20 September 2017

  13. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA579)

    This guidance has been replaced by NICE's technology appraisal guidance on abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.

    Technology appraisal guidance
    Published
    8 May 2019

  14. Menopause (QS143)

    This quality standard covers diagnosing and managing menopause in women, trans men and non-binary people registered female at birth, including those who have premature ovarian insufficiency (menopause before the age of 40, which can occur naturally or as a result of medical or surgical treatment). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    9 February 2017
    View quality statements

    Sections for QS143

  15. SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (DG5)

    Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver

    Diagnostics guidance
    Published
    29 August 2012
    View recommendations

    Sections for DG5